Renal Denervation Market to Reach USD 4743.13 Million by 2030, with a CAGR of 40.7%. Rise in the Cases of Hypertension and CHF to Drive the Market

Research analysts of Strategic Market Research delineated that Renal Denervation Market was worth USD 156 Million in 2020 & is forecasted to reach a remarkable landmark of nearly USD 4743.13 Million in 2030 with a CAGR of 40.7%. Rising cases of therapy-resistant hypertension, healthcare infrastructure improvement in emerging economies, rise in usage of the Radiofrequency Ablation, and the increasing cases of CHF (Congestive heart failure) drive the market growth.

Sambalpur, INDIA

New York, United States, May 31, 2022 (GLOBE NEWSWIRE) -- RDN or Renal denervation is a minimally invasive procedure to treat resistant hypertension. This procedure implements Radiofrequency Ablation to destroy the damaged tissues in the renal arteries to prevent cardiac blockage. This procedure causes a reduction in neural activity, which in turn decreases blood pressure. The key factors that are boosting the growth of the Global Renal denervation Market are the rise in the number of cases of hypertension, the increasing usage of the Radiofrequency Ablation and endovascular catheter, the continuous rise in the number of cases of CHF (Congestive heart failure), & atrial fibrillation. In terms of Technology, the radiofrequency ablation segment held the most significant market share of around 78.15% in 2020. Based on region, North America held the largest share with nearly 67.28% of the entire market. However, the Asia-Pacific (APAC) region witnessed the fastest growth rate with a burgeoning CAGR from 2020 to 2030. 

To get a first-hand overview of the report, Request a Sample at

The report featured by Strategic Market Research on the Renal Denervation Market is segmented based on:


  • Radiofrequency Ablation 
  • Micro-Infusion
  • Ultrasound 


North America

  • USA
  • Canada
  • Mexico
  • Rest of North America


  • Germany
  • Finland
  • Switzerland
  • France
  • Russian Federation
  • U.K
  • Finland
  • Turkey
  • Netherlands 
  • Belgium
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • India
  • Japan
  • Indonesia
  • South Korea
  • Thailand
  • Singapore
  • Malaysia
  • Philippines
  • New Zealand
  • Australia
  • Rest of APAC


  • Brazil
  • Uruguay
  • Saudi Arabia
  • Argentina
  • Rest of LAMEA

Make a Direct Purchase of the latest Renal Denervation Market Report published in the month of April 2022. Click the below link to initiate the purchase:

Report CoverageDetails
Forecast Period2020-2028
Forecast Period 2021 to 2028 CAGR40.7% 
2030 Value Projection4743.13 million
Base Year2020 
Market Size in 2020USD 156 million
Historical Data for2015 - 2019
No. of Pages135 
CompaniesAblative Solutions Inc, Abbott Laboratories, Johnson & Johnson, Cardiotonic Ltd, Boston Scientific Corporation, Medtronic plc, Mercator MedSystems, Inc, ReCor Medical, Inc, Renal Dynamics Limited, Terumo corporation
Leading SegmentBased on technologyRadiofrequency
 Leading RegionEurope
Segments coveredBy Technology and By Region
Growth Drivers

Rise in the cases of Hypertension
increasing cases of CHF (Congestive heart failure), use of Radiofrequency Ablation

Some of the essential factors driving the Market Growth:

One of the major reasons responsible for the propulsion of the market is the continuous rise in hypertension cases across the globe. As per Medscape, approximately 26% of the global population (i.e., around 972 million people) have hypertension, & the prevalence is expected to increase up to 29% by 2025. · Apart from the rise in hypertension cases, the growing usage of the endovascular catheters, Radiofrequency Ablation & the continuous rise in the number of cases of Congestive heart failures are driving the market growth extensively. As per Cleveland Clinic, around six million Americans suffer from cognitive heart failure, & more than 870k people are diagnosed with cardiac failure each year. Heart failure (congestive heart failure) is also one of the leading causes of hospitalization among people who are older than 65.

In terms of Technology, the Radiofrequency Ablation segment held the highest proportion of market share.

The market is segregated into Radiofrequency Ablation, Micro-Infusion, & Ultrasound in terms of technology. The radiofrequency ablation segment dominated the market with the highest share of around 78.15 %. Radiofrequency Ablation has many advantages like safety, time efficiency, etc. Moreover, Radiofrequency Ablation is a one-time procedure valid for at least two years to treat hypertension. All these factors are driving the growth of this segment efficiently. As per a research study, radiofrequency ablation is (70 to 80) % effective in people who have critical nerve blocks. Also, if a patient-level of relief is minimal after undergoing the radiofrequency ablation treatments, then it can be repeated after two or three weeks.

Europe held the largest proportion of market share during the forecasted period.

Based on Region, ‘’Europe” dominated the market comprehensively with a share of around 65.58% in 2020. This can be primarily attributed to the rise of government funding for increasing R&D activities & the continuously increasing cases of hypertension in the region. According to a research study, more than 40% of the Europeans over the age of 25 suffer from hypertension, & 10% of those possess medication-resistant hypertension (RHT). In 2020, the prevalence of hypertension was highest in Germany (around 55%), followed by Finland (nearly 49%), Spain (approximately 47%), England (around 42%), Sweden (about 38%), & Italy (nearly 38%).

Furthermore, the Asia Pacific (APAC) region is anticipated to witness the fastest growth rate over the forecast period because of the rising cases of diabetes, hypertension, obesity, & other lifestyle diseases. As per Saw Swee Hock School of Public Health, around 60% of diabetes patients live in Asia, out of which 113.9 million adults have diabetes in China, which constitutes around 11.6% of the total adult population.

Before initiating a purchase, make a Pre-order enquiry and get a detailed overview of the content of the report.

List of pertinent players existing in the Renal Denervation Market:

  • Abbott Laboratories
  • Ablative Solutions, Inc
  • Johnson & Johnson
  • Boston Scientific Corporation
  • Medtronic plc
  • Cardiotonic Ltd
  • Mercator MedSystems, Inc
  • ReCor Medical, Inc
  • Terumo Corporation
  • Renal Dynamics Limited

Kindly go through and get access to our comprehensive coverage of myriad number of healthcare reports published in the last three months:

Recent Developments:

  • On April 4th, 2022, Medtronic completed its Spyral HTN-ON MED trial testing on the RDN (Renal denervation) catheter system. This system delivers radiofrequency energy to the overactive nerves responsible for causing high blood pressure. The test results revealed that the RDN catheter system demonstrated durable and clinically significant BP reductions throughout the trial period of three years for patients on medication.

  • On October 6th, 2021, ReCor Medical successfully launched the Paradise Ultrasound Renal Denervation for the Treatment of Hypertension in the European Union. The Paradise Ultrasound Renal Denervation System is an ultrasound-based catheter integrated with a distal balloon that acts as a coolant for protecting the renal arterial wall. At present, this system is widely available in Deutschland.

  • On February 20th, 2020, Ablative Solutions, Inc announced the six-month results of the Peregrine Post-Market Study Trial. Results from this trial showed that the conduction of the renal denervation procedure through the Peregrine Catheter & alcohol as a neurolytic agent is 100% safe and effective for lowering the BP levels in patients.

Related Reports:

Radiofrequency Ablation Devices Market

SMR’s ‘Global Radiofrequency Ablation Devices Market Report with Insights & Forecast 2030’ elucidates a transparent idea regarding the pivotal market insights like the driving factors, restraints, opportunities, etc. In 2020, the Global Radio Frequency Ablation Devices Market was worth around USD 3.53 billion. It is predicted to reach a substantial benchmark of USD 10.726 billion by 2030 and a CAGR of 11.732%. Key reasons that are propelling the market growth extensively are the increase in the number of cardiovascular diseases & cancer cases, the continuous growth of the geriatric population, the rise in demand for pain management, etc. The key companies involved in the market are Boston Scientific Corporation, St. Jude Medical, Medtronic Plc, Stryker Corporation, C. R. Bard, Hologic, AtriCure, AngioDynamics, Johnson & Johnson, Baylis Medical, Arthrex, etc.

Minimally Invasive Surgical Instruments Market

SMR’s ‘Minimally Invasive Surgical Instruments Market Report Insights & Forecast 2030’ describes a clear-cut concept of crucial market insights like drivers, restraints, future opportunities, etc. In 2020, the Global Minimally Invasive Surgical Instruments Market share was valued up to USD 20.87 billion. It is predicted to rise up to USD 41.767 billion by 2030, with a decent CAGR value of 7.21%. The major factors that are accelerating the market growth are the continuous increase in the number of MI (minimally invasive) surgeries worldwide, the continuous increase in the geriatric population, the rising prevalence of several diseases like gastroesophageal reflux disease, Hiatal hernia, Benign prostatic hyperplasia (BPH), etc. The organizations associated with it are Medtronic plc, Stryker Corporation, Johnson & Johnson, Smith & Nephew plc, Abbott Laboratories, Inc., B. Braun Melsungen AG, CONMED Corporation, Boston Scientific Corporation, Zimmer Biomet Holdings Inc., etc.

Behavioural Health Software Market

SMR’s ‘Behavioural Health Software Market Report Insights & Forecast 2030’ encompasses a 360-degree understanding of the key market insights such as restraining factors, opportunities, drivers, etc. In 2020, the Global Behavioural Health Software Market share summed up to USD 2.16 billion. The market forecast suggests that by 2030, it would reach USD 7.61 billion, with a CAGR of 13.39%. The vital factors that are expediting the market growth are the increasing number of behavioral health issues, improvement in time efficiency, and the increasing adoption of behavioral health software. The key companies associated with this market are Advanced Data Systems, Cerner, Compulink, Core Solutions, Credible Behavioral Health, AdvancedMD, Kareo, Mindlinc, Netsmart, Nextgen Healthcare, Meditab Software, Qualifacts, The Echo Group, etc.

Neuroendoscopy Market

SMR’s ‘Neuroendoscopy Market Report Insights & Forecast 2030’ outlines a comprehensive idea of the vital marketing insights such as the key drivers, restraints, opportunities, etc. In 2020, the Global Neuroendoscopy Market share accounted for USD 176.51 million. The market is forecasted to reach USD 314.44 million at a CAGR of 5.94%. The continuous rising occurrence of various neurological diseases, and the increasing demand for minimally invasive surgical procedures, are increasing the market growth. The key players involved in this market are Charles River Laboratories International, Inc., Laboratory Corporation of America Holdings (Covance), The Jackson Laboratory, Perkin Elmer (Horizon Discovery Group plc), genOway, Envigo, etc.

Kidney Function Test Market

SMR’s ‘Kidney Function Test Market Report Insights & Forecast 2030’ delineates a crystal clear conception of the crucial insights of the market, such as drivers, opportunities, restraints, etc. The Global Kidney Function Test Market share was around USD 777.06 million. It is estimated to reach USD 1160.93 billion by 2028, with a CAGR of 6.9%. The pivotal factors accelerating the market growth are the ease of conducting various kidney function tests at home and the government’s rise in funding for the conduction of Research & Development activities. The pivotal players associated with this market are Unit Medical, Sysmex Corporation, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd., Randox Laboratories, Opti Medical, Nova Biomedical, Beckman Coulter, ARKRAY Inc., etc.

Central Nervous System (CNS) Biomarkers Market

SMR’s ‘Central Nervous System (CNS) Biomarkers Market Report Insights & Forecast 2030’ elucidates various market insights, like drivers, opportunities, restraints, etc. In 2020, the share of the Global CNS (Central Nervous System) Biomarkers Market was around USD 3.67 billion. It is estimated to reach around USD 8.7 billion by 2030, with a CAGR of nearly 9.0 %. The essential factors that augment the market growth are the rapid technological advancements, an increase in obesity leading to neurological illnesses, etc. The significant players operating in this market are Avacta Group plc, Diagenetic Asa, Banyan Biomarkers, Avid Radiopharmaceuticals Inc., Acumen Pharmaceuticals Inc., Siemens AG, etc.

About Us:
Strategic Market Research facilitates the organizations globally in taking pivotal business decisions by furnishing the Syndicated and Customized Research Reports, which are highly precise in terms of market numbers. We believe that every firm, whether it is a startup which is in the Introduction stage of the Product Life cycle or an established one which is at the growth stage, requires market research services in order to streamline its key business blueprint. It may be related to Product Launch, Go to Market strategies, Competitive Analysis or new geographical penetration and expansion.

Contact Us:
Strategic Market Research LLP.
Sunil Kumar 
US: +1-8317045538
UK: +441256636046
India: +91-8260836500
Press Release:

Connect Us: